Drug Database
Back to search

Poland· PL-100400601

Fotivda

A tivozanib product containing tivozanibi hydrochloridum monohydricum, registered in Poland by EUSA Pharma (Netherlands) B.V.. The same ATC class is registered in 10 of our 19 countries.

ATC L01EK03

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedFotivdaATCL01EK03REGISTER NO.PL-100400601PACKS LISTED1CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about tivozanibi hydrochloridum monohydricumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Tivozanib is registered in 10 of 19 countries.

Countries holding a registration under ATC L01EK03 (tivozanib), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 7 of them publish a price we can compare per daily dose
Search tivozanib products by name

Tivozanib · ATC L01EK03

10 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Tivozanibi hydrochloridum monohydricum
Manufacturer
EUSA Pharma (Netherlands) B.V.
Country
Poland (PL)
ATC code
L01EK03
ATC class
Tivozanib
Defined daily dose
1 mg, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    05060146291910

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

7 interactions on record for tivozanib.

Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check tivozanib against other medicinesHow interaction checks work

Tivozanib · interactions on record

7 records

  • 3 severe
  • 4 moderate

Most severe, free to view

  • PhenobarbitalN03AA02severe
  • PhenobarbitalN05CA24severe
  • Hyperici herbaN06AX25severe
  • RiociguatC02KX05moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Tivozanib in 11 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All tivozanib products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Fotivda
  • Liechtenstein · Fotivda
  • Norway · Fotivda

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/0392ffb0-0093-4125-8fd9-170aa7e79884
GET /v1/drugs/0392ffb0-0093-4125-8fd9-170aa7e79884?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Kapsułki twarde",
  "source": "urpl",
  "strength": "1340 mcg",
  "packaging": "05060146291910 ¦ Rpz ¦ EU/1/17/1215/002 ¦ 126549\n21 kaps.",
  "substance": "Tivozanibi hydrochloridum monohydricum 1340 mcg",
  "common_name": "Tivozanibi hydrochloridum monohydricum",
  "pl_product_id": "100400601",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about tivozanib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console